Syndax Pharmaceuticals (SNDX) Stock Forecast, Price Target & Predictions
SNDX Stock Forecast
Syndax Pharmaceuticals stock forecast is as follows: an average price target of $36.00 (represents a 88.28% upside from SNDX’s last price of $19.12) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
SNDX Price Target
The average price target for Syndax Pharmaceuticals (SNDX) is $36.00 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $41.00 to $31.00. This represents a potential 88.28% upside from SNDX's last price of $19.12.
SNDX Analyst Ratings
According to 8 Wall Street analysts, Syndax Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for SNDX stock is 0 'Strong Buy' (0.00%), 8 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Syndax Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 15, 2024 | Yigal Nochomovitz | Citigroup | $34.00 | $20.09 | 69.24% | 77.82% |
| Aug 15, 2024 | Jason Zemansky | Bank of America Securities | $31.00 | $19.58 | 58.32% | 62.13% |
| Aug 15, 2024 | Peter Lawson | Barclays | $33.00 | $19.58 | 68.54% | 72.59% |
| Jul 30, 2024 | Jason Zemansky | Bank of America Securities | $30.00 | $21.99 | 36.43% | 56.90% |
| Jun 28, 2024 | Kelly Shi | Jefferies | $37.00 | $20.32 | 82.09% | 93.51% |
| May 09, 2024 | Bradley Canino | Stifel Nicolaus | $40.00 | $22.38 | 78.73% | 109.21% |
| Jan 03, 2023 | - | J.P. Morgan | $41.00 | $26.32 | 55.75% | 114.44% |
| Dec 12, 2022 | - | Goldman Sachs | $39.00 | $23.39 | 66.74% | 103.97% |
| Dec 12, 2022 | - | H.C. Wainwright | $33.00 | $20.64 | 59.88% | 72.59% |
The latest Syndax Pharmaceuticals stock forecast, released on Aug 15, 2024 by Yigal Nochomovitz from Citigroup, set a price target of $34.00, which represents a 69.24% increase from the stock price at the time of the forecast ($20.09), and a 77.82% increase from SNDX last price ($19.12).
Syndax Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 5 | 6 |
| Avg Price Target | - | $33.00 | $34.17 |
| Last Closing Price | $19.12 | $19.12 | $19.12 |
| Upside/Downside | -100.00% | 72.59% | 78.71% |
In the current month, the average price target of Syndax Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Syndax Pharmaceuticals's last price of $19.12. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 15, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 15, 2024 | Citigroup | Buy | Buy | Hold |
| Aug 15, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 15, 2024 | Barclays | Overweight | Overweight | Hold |
| Jul 30, 2024 | Bank of America Securities | Buy | Buy | Hold |
| Jun 28, 2024 | Jefferies | - | Buy | Initialise |
| May 09, 2024 | Citigroup | Buy | Buy | Hold |
| Jul 26, 2023 | Citigroup | Buy | Buy | Hold |
| Jul 11, 2023 | Guggenheim | - | Buy | Initialise |
| Dec 12, 2022 | Goldman Sachs | Buy | Buy | Hold |
Syndax Pharmaceuticals's last stock rating was published by Cowen & Co. on Aug 15, 2024. The company gave SNDX a "Buy" rating, the same as its previous rate.
Syndax Pharmaceuticals Financial Forecast
Syndax Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | Mar 18 | Sep 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $536.00K | - | - | - | - | - | $126.58M | $12.38M | $379.00K | $379.00K | $379.00K | $379.00K | $379.00K | $379.00K | $379.00K | $379.00K | $379.00K | $379.00K | $379.00K | $379.00K | $379.00K | $305.00K |
| Avg Forecast | $39.15M | $25.80M | $19.05M | $15.65M | $25.67M | $5.18M | $142.86K | $142.86K | $536.00K | $600.00K | $1.33M | $750.00K | $1.38M | $2.56M | $6.29M | $29.41M | $225.00K | $225.00K | $100.00K | $200.00K | $390.00K | $384.75K | $364.50K | $364.50K | $371.60K | $364.75K | $423.59K | $445.58K | $460.56K | $358.82K |
| High Forecast | $39.15M | $25.80M | $19.05M | $15.65M | $25.67M | $14.17M | $142.86K | $142.86K | $536.00K | $600.00K | $1.33M | $750.00K | $1.66M | $2.56M | $6.29M | $29.41M | $225.00K | $225.00K | $100.00K | $200.00K | $390.00K | $384.75K | $364.50K | $364.50K | $371.60K | $364.75K | $508.30K | $534.70K | $552.67K | $430.59K |
| Low Forecast | $39.15M | $25.80M | $19.05M | $15.65M | $25.67M | $226.64K | $142.86K | $142.86K | $536.00K | $600.00K | $1.33M | $750.00K | $1.09M | $2.56M | $6.29M | $29.41M | $225.00K | $225.00K | $100.00K | $200.00K | $390.00K | $384.75K | $364.50K | $364.50K | $371.60K | $364.75K | $338.87K | $356.46K | $368.44K | $287.06K |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 7 | 4 | 3 | 3 | 1 | 3 | 4 | 5 | 6 | 11 | 12 | 16 | 9 | 9 | 8 | 9 | 13 | 17 | 19 | 19 | 15 | 15 |
| Surprise % | - | - | - | - | - | - | - | - | 1.00% | - | - | - | - | - | 20.12% | 0.42% | 1.68% | 1.68% | 3.79% | 1.90% | 0.97% | 0.99% | 1.04% | 1.04% | 1.02% | 1.04% | 0.89% | 0.85% | 0.82% | 0.85% |
Syndax Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 4 analysts is $142.86K, with a low forecast of $142.86K, and a high forecast of $142.86K. SNDX's average Quarter revenue forecast represents a -73.35% decrease compared to the company's last Quarter revenue of $536.00K (Dec 23).
Syndax Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | Mar 18 | Sep 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 7 | 4 | 3 | 3 | 1 | 3 | 4 | 5 | 6 | 11 | 12 | 16 | 9 | 9 | 8 | 9 | 13 | 17 | 19 | 19 | 15 | 15 |
| EBITDA | - | - | - | - | - | - | - | - | $-72.63M | $-46.02M | $-42.03M | $-33.65M | - | $-36.51M | $96.21M | $-19.98M | $-22.27M | $-27.08M | $-19.77M | $-19.78M | $-16.40M | $-14.76M | $-13.55M | $-12.83M | $-14.92M | $-14.12M | $-17.19M | $-18.31M | $-19.34M | $-14.93M |
| Avg Forecast | $1.47M | $968.41K | $715.04K | $587.42K | $963.67K | $194.39K | $5.36K | $5.36K | $20.12K | $22.52K | $50.05K | $28.15K | $51.61K | $96.18K | $236.16K | $-19.33M | $-28.16M | $-31.67M | $3.75K | $-18.88M | $-17.50M | $-13.32M | $13.68K | $-14.47M | $-13.53M | $-14.88M | $-19.00M | $-21.05M | $-22.76M | $-17.17M |
| High Forecast | $1.47M | $968.41K | $715.04K | $587.42K | $963.67K | $531.70K | $5.36K | $5.36K | $20.12K | $22.52K | $50.05K | $28.15K | $62.43K | $96.18K | $236.16K | $-15.47M | $-22.53M | $-25.33M | $3.75K | $-15.10M | $-14.00M | $-10.65M | $13.68K | $-11.57M | $-10.82M | $-11.90M | $-15.20M | $-16.84M | $-18.21M | $-13.74M |
| Low Forecast | $1.47M | $968.41K | $715.04K | $587.42K | $963.67K | $8.51K | $5.36K | $5.36K | $20.12K | $22.52K | $50.05K | $28.15K | $40.79K | $96.18K | $236.16K | $-23.20M | $-33.80M | $-38.00M | $3.75K | $-22.66M | $-20.99M | $-15.98M | $13.68K | $-17.36M | $-16.23M | $-17.85M | $-22.80M | $-25.26M | $-27.31M | $-20.61M |
| Surprise % | - | - | - | - | - | - | - | - | -3610.40% | -2043.20% | -839.89% | -1195.23% | - | -379.56% | 407.39% | 1.03% | 0.79% | 0.86% | -5266.99% | 1.05% | 0.94% | 1.11% | -990.72% | 0.89% | 1.10% | 0.95% | 0.90% | 0.87% | 0.85% | 0.87% |
3 analysts predict SNDX's average Quarter EBITDA for Mar 22 to be $96.18K, with a high of $96.18K and a low of $96.18K. This is -99.90% lower than Syndax Pharmaceuticals's previous annual EBITDA (Dec 21) of $96.21M.
Syndax Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | Mar 18 | Sep 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 7 | 4 | 3 | 3 | 1 | 3 | 4 | 5 | 6 | 11 | 12 | 16 | 9 | 9 | 8 | 9 | 13 | 17 | 19 | 19 | 15 | 15 |
| Net Income | - | - | - | - | - | - | - | - | $-77.41M | $-36.19M | $-36.31M | $-35.66M | - | $-37.48M | $96.20M | $-20.64M | $-22.91M | $-27.72M | $-20.42M | $-20.44M | $-17.06M | $-15.24M | $-14.00M | $-12.83M | $-14.92M | $-14.30M | $-17.34M | $-18.39M | $-19.40M | $-15.09M |
| Avg Forecast | $-62.68M | $-76.32M | $-82.29M | $-84.00M | $-81.96M | $-96.07M | $-77.67M | $-83.44M | $-70.23M | $-50.80M | $-55.29M | $-54.15M | $-54.25M | $-46.05M | $-42.54M | $-19.97M | $-28.98M | $-32.41M | $-35.32M | $-19.51M | $-18.20M | $-13.74M | $-30.98M | $-14.47M | $-13.53M | $-15.07M | $-19.16M | $-21.14M | $-22.83M | $-17.35M |
| High Forecast | $-62.68M | $-76.32M | $-82.29M | $-84.00M | $-81.96M | $-89.27M | $-77.67M | $-83.44M | $-65.26M | $-50.80M | $-55.29M | $-54.15M | $-39.46M | $-46.05M | $-42.54M | $-15.97M | $-23.18M | $-25.93M | $-35.32M | $-15.61M | $-14.56M | $-10.99M | $-30.98M | $-11.57M | $-10.82M | $-12.05M | $-15.33M | $-16.91M | $-18.27M | $-13.88M |
| Low Forecast | $-62.68M | $-76.32M | $-82.29M | $-84.00M | $-81.96M | $-107.13M | $-77.67M | $-83.44M | $-81.58M | $-50.80M | $-55.29M | $-54.15M | $-69.04M | $-46.05M | $-42.54M | $-23.96M | $-34.77M | $-38.90M | $-35.32M | $-23.41M | $-21.84M | $-16.49M | $-30.98M | $-17.36M | $-16.23M | $-18.08M | $-23.00M | $-25.36M | $-27.40M | $-20.82M |
| Surprise % | - | - | - | - | - | - | - | - | 1.10% | 0.71% | 0.66% | 0.66% | - | 0.81% | -2.26% | 1.03% | 0.79% | 0.86% | 0.58% | 1.05% | 0.94% | 1.11% | 0.45% | 0.89% | 1.10% | 0.95% | 0.90% | 0.87% | 0.85% | 0.87% |
Syndax Pharmaceuticals's average Quarter net income forecast for Mar 22 is $-46.05M, with a range of $-46.05M to $-46.05M. SNDX's average Quarter net income forecast represents a -147.87% decrease compared to the company's last Quarter net income of $96.20M (Dec 21).
Syndax Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | Mar 18 | Sep 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 7 | 4 | 3 | 3 | 1 | 3 | 4 | 5 | 6 | 11 | 12 | 16 | 9 | 9 | 8 | 9 | 13 | 17 | 19 | 19 | 15 | 15 |
| SG&A | - | - | - | - | - | - | - | - | $22.78M | $11.96M | $10.19M | $8.24M | - | $6.84M | $6.93M | $6.80M | $5.84M | $5.67M | $4.72M | $5.82M | $6.05M | $5.92M | $5.08M | $3.60M | $3.46M | $3.91M | $4.13M | $4.48M | $4.79M | $3.56M |
| Avg Forecast | $216.14M | $142.44M | $105.17M | $86.40M | $141.74M | $28.59M | $788.68K | $788.68K | $2.96M | $3.31M | $7.36M | $4.14M | $7.59M | $14.15M | $34.73M | $6.58M | $1.24M | $1.24M | $552.08K | $1.10M | $2.15M | $2.12M | $2.01M | $2.01M | $2.05M | $2.01M | $2.34M | $2.46M | $2.54M | $1.98M |
| High Forecast | $216.14M | $142.44M | $105.17M | $86.40M | $141.74M | $78.20M | $788.68K | $788.68K | $2.96M | $3.31M | $7.36M | $4.14M | $9.18M | $14.15M | $34.73M | $7.90M | $1.24M | $1.24M | $552.08K | $1.10M | $2.15M | $2.12M | $2.01M | $2.01M | $2.05M | $2.01M | $2.81M | $2.95M | $3.05M | $2.38M |
| Low Forecast | $216.14M | $142.44M | $105.17M | $86.40M | $141.74M | $1.25M | $788.68K | $788.68K | $2.96M | $3.31M | $7.36M | $4.14M | $6.00M | $14.15M | $34.73M | $5.26M | $1.24M | $1.24M | $552.08K | $1.10M | $2.15M | $2.12M | $2.01M | $2.01M | $2.05M | $2.01M | $1.87M | $1.97M | $2.03M | $1.58M |
| Surprise % | - | - | - | - | - | - | - | - | 7.70% | 3.61% | 1.38% | 1.99% | - | 0.48% | 0.20% | 1.03% | 4.70% | 4.57% | 8.55% | 5.27% | 2.81% | 2.79% | 2.53% | 1.79% | 1.69% | 1.94% | 1.76% | 1.82% | 1.88% | 1.80% |
Syndax Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $788.68K, based on 4 Wall Street analysts, with a range of $788.68K to $788.68K. The forecast indicates a -96.54% fall compared to SNDX last annual SG&A of $22.78M (Dec 23).
Syndax Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | Mar 18 | Sep 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 7 | 4 | 3 | 3 | 1 | 3 | 4 | 5 | 6 | 11 | 12 | 16 | 9 | 9 | 8 | 9 | 13 | 17 | 19 | 19 | 15 | 15 |
| EPS | - | - | - | - | - | - | - | - | $1.89 | $-0.52 | $-0.57 | $-0.59 | - | $-0.64 | $1.81 | $-0.40 | $-0.44 | $-0.54 | $-0.44 | $-0.46 | $-0.42 | $-0.56 | $-0.44 | $-0.41 | $-0.47 | $-0.53 | $-0.68 | $-0.74 | $-0.79 | $-0.68 |
| Avg Forecast | $-0.73 | $-0.90 | $-0.96 | $-0.98 | $-0.96 | $-1.13 | $-0.91 | $-0.98 | $-0.97 | $-0.60 | $-0.65 | $-0.64 | $-0.64 | $-0.64 | $-0.59 | $-0.16 | $-0.71 | $-0.65 | $-0.49 | $-0.44 | $-0.45 | $-0.50 | $-0.43 | $-0.47 | $-0.45 | $-0.56 | $-0.84 | $-1.00 | $-1.13 | $-0.92 |
| High Forecast | $-0.73 | $-0.90 | $-0.96 | $-0.98 | $-0.96 | $-1.05 | $-0.91 | $-0.98 | $-0.90 | $-0.60 | $-0.65 | $-0.64 | $-0.46 | $-0.64 | $-0.59 | $-0.16 | $-0.71 | $-0.65 | $-0.49 | $-0.44 | $-0.45 | $-0.50 | $-0.43 | $-0.47 | $-0.45 | $-0.56 | $-0.67 | $-0.80 | $-0.90 | $-0.74 |
| Low Forecast | $-0.73 | $-0.90 | $-0.96 | $-0.98 | $-0.96 | $-1.26 | $-0.91 | $-0.98 | $-1.12 | $-0.60 | $-0.65 | $-0.64 | $-0.81 | $-0.64 | $-0.59 | $-0.16 | $-0.71 | $-0.65 | $-0.49 | $-0.44 | $-0.45 | $-0.50 | $-0.43 | $-0.47 | $-0.45 | $-0.56 | $-1.01 | $-1.20 | $-1.36 | $-1.10 |
| Surprise % | - | - | - | - | - | - | - | - | -1.95% | 0.87% | 0.88% | 0.93% | - | 1.01% | -3.09% | 2.46% | 0.62% | 0.83% | 0.90% | 1.05% | 0.94% | 1.12% | 1.03% | 0.87% | 1.04% | 0.95% | 0.81% | 0.74% | 0.70% | 0.74% |
According to 4 Wall Street analysts, Syndax Pharmaceuticals's projected average Quarter EPS for Mar 24 is $-0.98, with a low estimate of $-0.98 and a high estimate of $-0.98. This represents a -151.77% decrease compared to SNDX previous annual EPS of $1.89 (Dec 23).
Syndax Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| AVTE | Aerovate Therapeutics | $1.90 | $13.00 | 584.21% | Hold |
| PLRX | Pliant Therapeutics | $12.00 | $39.71 | 230.92% | Buy |
| MLYS | Mineralys Therapeutics | $11.76 | $30.00 | 155.10% | Buy |
| EWTX | Edgewise Therapeutics | $18.83 | $48.00 | 154.91% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| STRO | Sutro Biopharma | $4.50 | $10.80 | 140.00% | Buy |
| KALV | KalVista Pharmaceuticals | $11.14 | $26.00 | 133.39% | Buy |
| REPL | Replimune Group | $11.13 | $24.20 | 117.43% | Buy |
| LRMR | Larimar Therapeutics | $7.20 | $14.50 | 101.39% | Buy |
| SNDX | Syndax Pharmaceuticals | $19.12 | $36.00 | 88.28% | Buy |
| KROS | Keros Therapeutics | $56.98 | $105.00 | 84.28% | Buy |
| CGEM | Cullinan Oncology | $17.95 | $32.00 | 78.27% | Buy |
| COGT | Cogent Biosciences | $10.63 | $18.50 | 74.04% | Buy |
| VRDN | Viridian Therapeutics | $22.06 | $37.83 | 71.49% | Buy |
| MRUS | Merus | $50.14 | $77.86 | 55.29% | Buy |
| CYTK | Cytokinetics | $55.88 | $80.92 | 44.81% | Buy |
| MRSN | Mersana Therapeutics | $2.11 | $3.00 | 42.18% | Buy |
| DYN | Dyne Therapeutics | $34.06 | $43.88 | 28.83% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $43.70 | $51.20 | 17.16% | Buy |
| PCVX | Vaxcyte | $116.00 | $124.14 | 7.02% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
SNDX Forecast FAQ
Is Syndax Pharmaceuticals a good buy?
Yes, according to 8 Wall Street analysts, Syndax Pharmaceuticals (SNDX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 8 'Buy' recommendations, accounting for 100.00% of SNDX's total ratings.
What is SNDX's price target?
Syndax Pharmaceuticals (SNDX) average price target is $36 with a range of $31 to $41, implying a 88.28% from its last price of $19.12. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Syndax Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for SNDX stock, the company can go up by 88.28% (from the last price of $19.12 to the average price target of $36), up by 114.44% based on the highest stock price target, and up by 62.13% based on the lowest stock price target.
Can Syndax Pharmaceuticals stock reach $30?
SNDX's average twelve months analyst stock price target of $36 supports the claim that Syndax Pharmaceuticals can reach $30 in the near future.
What are Syndax Pharmaceuticals's analysts' financial forecasts?
Syndax Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $31.14M (high $40.12M, low $26.19M), average EBITDA is $1.17M (high $1.51M, low $982.9K), average net income is $-339M (high $-332M, low $-350M), average SG&A $171.91M (high $221.52M, low $144.57M), and average EPS is $-3.977 (high $-3.897, low $-4.107). SNDX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $99.65M (high $99.65M, low $99.65M), average EBITDA is $3.74M (high $3.74M, low $3.74M), average net income is $-305M (high $-305M, low $-305M), average SG&A $550.15M (high $550.15M, low $550.15M), and average EPS is $-3.58 (high $-3.58, low $-3.58).
Did the SNDX's actual financial results beat the analysts' financial forecasts?
Based on Syndax Pharmaceuticals's last annual report (Dec 2021), the company's revenue was $139.71M, beating the average analysts forecast of $36.15M by 286.43%. Apple's EBITDA was $26.22M, missing the average prediction of $-78.928M by -133.22%. The company's net income was $24.93M, missing the average estimation of $-124M by -120.12%. Apple's SG&A was $25.24M, missing the average forecast of $43.8M by -42.37%. Lastly, the company's EPS was $0.48, missing the average prediction of $-2.113 by -122.72%. In terms of the last quarterly report (Dec 2023), Syndax Pharmaceuticals's revenue was $536K, beating the average analysts' forecast of $536K by 0%. The company's EBITDA was $-72.634M, missing the average prediction of $20.12K by -361139.86%. Syndax Pharmaceuticals's net income was $-77.405M, beating the average estimation of $-70.226M by 10.22%. The company's SG&A was $22.78M, beating the average forecast of $2.96M by 669.79%. Lastly, the company's EPS was $1.89, missing the average prediction of $-0.968 by -295.18%